Testing a New Immune-Modulating Treatment for Recently Diagnosed Type 1 Diabetes

This trial is testing rezpegaldesleukin, an experimental medication designed to modify the immune system's attack on insulin-producing cells in type 1 diabetes. The study will enroll 66 people who have been diagnosed with type 1 diabetes within the past 100 days. Half will receive the medication, and half will receive a placebo (inactive injection), to see if this treatment can help preserve the body's remaining ability to produce its own insulin.

Type 1 diabetes happens when the immune system mistakenly attacks the cells that make insulin. Once diagnosed, people have lost most—but not all—of their insulin-producing cells. This trial is testing whether this medication can help slow or stop that immune attack and preserve the remaining insulin-producing ability, which could reduce how much insulin people need to inject.